Handelsbanken Fonder’s Heron Therapeutics HRTX Stock Holding History

Handelsbanken Fonder’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-28,000	Closed	-$160K	–	1650
2022 Q1	$160K	Hold	28,000	–	–	﹤0.01%	1655
2021 Q4	$256K	Hold	28,000	–	–	﹤0.01%	1654
2021 Q3	$299K	Hold	28,000	–	–	﹤0.01%	1592
2021 Q2	$435K	Buy	28,000 +6,300	+29%	+$100K	﹤0.01%	1480
2021 Q1	$352K	Buy	21,700 +8,700	+67%	+$155K	﹤0.01%	1380
2020 Q4	$275K	Hold	13,000	–	–	﹤0.01%	1442
2020 Q3	$193K	Hold	13,000	–	–	﹤0.01%	1393
2020 Q2	$191K	Buy	+13,000	New	+$214K	﹤0.01%	1382

Other funds holding HRTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Handelsbanken Fonder's HRTX Position: Q2 2022 in Review

Handelsbanken Fonder sold out of Heron Therapeutics (HRTX) in Q2 2022, closing a stake of 28,000 shares — an estimated $160K sold.

Handelsbanken Fonder first reported a position in HRTX in Q2 2020 and held it in 8 quarters. The position peaked at $435K in Q2 2021. 174 funds tracked by Wall St. Rank hold HRTX as of Q2 2022.

Handelsbanken Fonder reported no remaining Heron Therapeutics position as of Q2 2022 after selling out during the quarter.
Handelsbanken Fonder sold 28,000 Heron Therapeutics shares in Q2 2022, an estimated $160K.
Handelsbanken Fonder first reported a position in Heron Therapeutics in Q2 2020 and held it in 8 quarters.
Handelsbanken Fonder's Heron Therapeutics position peaked at $435K in Q2 2021.
174 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2022.

Based on Handelsbanken Fonder's 13F filing for Q2 2022, filed 3 Aug 2022.